MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions currently trading at $3.12 with a market capitalization of $18.43 million, has announced the postponement of its Special Meeting of Stockholders, which was originally set for Friday. According to InvestingPro analysis, the company maintains impressive gross profit margins of 67% despite challenging market conditions. The meeting will now take place on Thursday, April 10, 2025, at 12:00 p.m. Eastern Time, and will be conducted virtually via live audio webcast.
The decision to delay the meeting is to allow additional time for the solicitation of proxies from stockholders and to enable more stockholder participation in the voting process. The record date for determining stockholders eligible to vote remains set for March 14, 2025.
Stockholders who have already voted do not need to take further action unless they wish to modify or revoke their vote. Their existing votes will be counted at the rescheduled meeting. Allurion’s management urges stockholders who have not yet voted to do so promptly to ensure their representation.
The Board of Directors of Allurion recommends a vote FOR the proposals outlined in the Definitive Proxy Statement, which was filed with the U.S. Securities and Exchange Commission on March 24, 2025. The proxy statement contains important information regarding the proposals to be considered at the Special Meeting. With the stock experiencing significant volatility and a 69% decline year-to-date, investors seeking deeper insights can access comprehensive analysis through InvestingPro, which offers exclusive financial health metrics and 16 additional expert tips for ALUR.
Allurion emphasizes the importance of stockholder votes at the Special Meeting, regardless of the number of shares held. Voting proxies can be revoked by stockholders if they choose to attend and vote at the postponed meeting.
About Allurion, the company is committed to addressing obesity through its Allurion Program, which includes a swallowable gastric balloon, a virtual care suite, and a connected scale. The company’s next earnings report is scheduled for May 14, 2025, and detailed financial projections are available through InvestingPro’s exclusive Research Reports, which provide comprehensive analysis of the company’s financial health and growth prospects. The Allurion Gastric Balloon is currently an investigational device in the United States.
The press release also contains forward-looking statements regarding the expected timing and outcomes of the Special Meeting, regulatory approvals, and market opportunities, among other aspects. These statements involve risks and uncertainties that could cause actual results to differ materially from projections.
This article is based on a press release statement from Allurion Technologies, Inc.
In other recent news, Allurion Technologies reported a notable decline in its fourth-quarter 2024 earnings, with revenue dropping to $5.6 million from $8.2 million in the same period the previous year. Despite this, the company managed to decrease operating expenses by 39% year-over-year and raised an additional $15 million in net cash through equity offerings in early 2025. Allurion’s management projects a revenue forecast of $30 million for 2025, an 8% decrease from 2024. Analysts from Chardan Capital Markets maintained a Neutral rating on Allurion, with a price target of $2.50, suggesting tempered expectations for the company’s performance. Additionally, Allurion received regulatory clearance from the French National Agency for the Safety of Medicines and Health Products to resume sales of its flagship product in France, although analysts predict minimal revenue contribution from this market in 2025. The company is also focusing on strategic initiatives, including product innovations and potential U.S. market entry, pending FDA approval. Meanwhile, TD Cowen analyst Joshua Jennings highlighted Allurion as one of the firms expected to be least impacted by new U.S. tariff policies due to its domestic manufacturing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.